Xbrane Biopharma Announces SEK 240 Million Directed Share Issue to Boost Biosimilar Development

Xbrane Biopharma AB ( (SE:XBRANE) ) has issued an announcement.

Xbrane Biopharma AB has announced a directed share issue, subject to approval by an Extraordinary General Meeting, to raise approximately SEK 240 million. This funding will support the company’s regulatory processes, production costs, and general corporate purposes, positioning Xbrane to capitalize on its biosimilar products, Ximluci® and Xdivane™, and potentially achieve cash-flow positivity. The recent transaction with Alvotech, involving the sale of a biosimilar candidate and organizational restructuring, is expected to significantly reduce Xbrane’s fixed costs and enhance its financial flexibility, enabling a stronger focus on its core biosimilar programs.

More about Xbrane Biopharma AB

Xbrane Biopharma AB operates in the biopharmaceutical industry, focusing on the development and commercialization of biosimilars, which are biologic medical products highly similar to already approved reference products. The company aims to leverage its expertise in this field to provide cost-effective alternatives to existing biologic therapies.

Average Trading Volume: 20,245,794

Current Market Cap: SEK379.4M

See more insights into XBRANE stock on TipRanks’ Stock Analysis page.